A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)

Submission date	Recruitment status No longer recruiting	Prospectively registered		
08/11/2013		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
08/11/2013	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
09/08/2019	Nervous System Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mrs joanne Morrison

Contact details

Institute of Health and Society 4th Floor William Leech Building Framlington Place Newcastle Upon Tyne United Kingdom NE2 4HH

joanne.morrison@ncl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS) 2012-000845-11

ClinicalTrials.gov (NCT)

NCT01741532

Protocol serial number

15679

Study information

Scientific Title

TIRCON: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate kinase-associated neurodegeneration (PKAN)

Acronym

TIRCON

Study objectives

- 1. To evaluate the change in severity of dystonia (BAD scale) in patients with PKAN treated with deferiprone for 18 months compared to placebo.
- 2. To evaluate the patients global impression of conditions improvement in patients treated with deferiprone for 18 months compared to placebo (PGI-I).

Ethics approval required

Old ethics approval format

Ethics approval(s)

13/YH/0171

Study design

Randomised; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Medicines for Children Research Network; Subtopic: All Diagnoses; Disease: All Diseases

Interventions

Main Intervention, Haematology
UPDRS (Unified Parkinson's Disease Rating Scale)
PK Sample collection (in a subset of patients)
Genetic Sample (only taken in patients who experience neutropenia)

Intervention Type

Other

Phase

Phase III

Primary outcome(s)

Change in the BarryAlbrightDystonia Scale (BAD) total score from baseline to month 18 in patients

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/07/2015

Eligibility

Kev inclusion criteria

- 1. Males and females 4 years of age and older at screening visit
- 2 .Patients must have PKAN, confirmed by genetic testing
- 3. Patients having a BAD total score > = 3 at the screening visit
- 4. Patients who have Deep Brain Stimulation (DBS) systems or baclofen pumps in place will be eligible for the study, but they must have had a stable setting for at least 2 months prior to the screening visit and stimulation parameters /pump settings must remain stable for the duration of the trial. Enrollment of nonDBS patients will be given priority in order to ensure the majority can undergo imaging
- 5. Potentially sexually active female patients of childbearing potential must have a negative pregnancy test result at Screening Visit (if applicable; in cases where the Investigator determines there is no reasonable risk of pregnancy because of significant incapacity, pregnancy testing will not be performed)
- 6. Fertile potentially sexually active males must use an effective method of contraception or must confirm partners use of effective contraception
- 7. Informed consent/assent obtained before any studyrelated activities are undertaken
- 8. Ability and willingness to adhere to the protocol including appointments and evaluation schedule

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Child

Lower age limit

4 years

Sex

All

Key exclusion criteria

- 1. Evidence of iron deficiency defined by Fe:TIBC ratio <15%, or serum ferritin < 12 ng/mL
- 2. Treatment with deferiprone in the past 12 months
- 3. Previous failure of treatment with deferiprone, or previous discontinuation of treatment with deferiprone due to adverse events

- 4. Evidence of abnormal liver or renal function (serum liver enzyme level(s) > 3 times upper limit of normal at screening) or abnormal creatinine levels at screening visit
- 5. Disorders associated with neutropenia (absolute neutrophil count (ANC) $< 1.5 \times 109/L$) or thrombocytopenia (platelet count $< 50 \times 109/L$) in the 12 months preceding the initiation of the study medication. Exception: for patients whose neutropenia was attributed by the treating physician to episodes of infection or to drugs associated with a decline in the neutrophil count and in whom ANC has fully recovered at the screening visit
- 6. Pregnant, breastfeeding, or planning to become pregnant during the study
- 7. Initiation or discontinuation of treatment with baclofen, trihexyphenidyl, clonazepam, tizanidine within 30 days prior to baseline; and initiation or discontinuation of treatment with tetrabenazine within 90 days prior to baseline
- 8. Treatment with an investigational drug within 30 days or 5 halflives (whichever is longer) preceding the baseline
- 9. Currently taking iron chelators
- 10. Patients who, in the opinion of the physician, represent a high medical or psychological risk
- 11. History of or active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
- 12. Patients and patient's legal representative (if applicable) with a mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
- 13. Baclofen pump placement less than two months prior to the beginning of the study

Date of first enrolment 01/07/2013

Date of final enrolment 01/07/2015

Locations

Countries of recruitmentUnited Kingdom

England

Study participating centre
Institute of Health and Society
Newcastle Upon Tyne
United Kingdom
NE2 4HH

Sponsor information

Organisation

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

ROR

Funder(s)

Funder type

Government

Funder Name

European Commission

Alternative Name(s)

European Union, Comisión Europea, Europäische Kommission, EU-Kommissionen, Euroopa Komisjoni, EC, EU

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2019	09/08/2019	Yes	No
Basic results			09/08/2019	No	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes